Analyst Alerts Archives - Page 26 of 37

FridayJun 02, 2017 11:34 am

NetworkNewsBreak – Asure Software, Inc. (NASDAQ: ASUR) Engages ROTH Capital as Sole Book-Running Manager in $29.5M Public Offering

Asure Software (NASDAQ: ASUR) has successfully completed an underwritten public offering of 2,185,000 shares of its common stock at the public offering price of $13.50 per share, which includes the sale of 285,000 additional shares pursuant to the full exercise of the over-allotment option granted to the underwriters. ROTH Capital Partners acted as the sole book-running manager for the offering. Gross proceeds for Asure totaled $29.5 million, which the company plans to use toward general corporate purposes and to potentially acquire or invest in complementary businesses, assets or technologies. The company has not entered into any definitive agreement with respect…

FridayJun 02, 2017 8:00 am

NetworkNewsBreak – Exactus, Inc. (EXDI) Receives $1.60 PT from SeeThruEquity

SeeThruEquity has initiated coverage and issued a price target of $1.60 on shares of Exactus, Inc. (OTCQB: EXDI). The analyst noted that the company has an intriguing lineup of point-of-care (POC) diagnostic solutions designed to improve the markets for fibrinolytic and cancer screening. Exactus’ initial products, the FibriLyzer™ and MatriLyzer™, are POC diagnostics that can produce results from only a drop of blood, saving time and cost compared to the currently available methods. The market for POC diagnostics is set to reach to $26.3 billion by 2021, and the analyst believes the company’s diagnostics have the potential to be disruptive…

ThursdayJun 01, 2017 8:38 am

NetworkNewsBreaks – SeeThruEquity Updates Coverage with $0.65 PT on Innovus Pharmaceuticals, Inc. (OTCQB: INNV)

SeeThruEquity has issued an update and $0.65 price target on shares of Innovus Pharmaceuticals, Inc. (OTCQB: INNV) following the company's launch of AllerVarx™ in the U.S. and the report of financial results for the first quarter of 2017. Highlights from the report include revenue of $2.2 million, a 865% increase compared to $0.2 million for the same period of the previous year. The analyst said the increase demonstrates sustained sales execution, placing Innovus on track to achieve its full-year guidance for $10 million - $15 million. The company is also expanding sales channels for its portfolio of 18 commercial products.…

WednesdayMay 31, 2017 1:05 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on CytoSorbents Corp. (NASDAQ: CTSO)

Following CytoSorbents Corp.’s (NASDAQ: CTSO) appointment of a new chief medical officer (CMO), Aegis Capital reiterated its ‘Buy’ rating and price target of $9 on shares of the company’s stock. The company recently named Dr. Eric G. Mortensen, M.D., Ph.D., as its new CMO, starting full-time tomorrow. Dr. Mortensen holds an M.D. from Harvard University and Massachusetts Institute of Technology Division of Health Sciences and Technology, and a Ph.D. in biophysics from the Harvard Graduate School of Arts and Sciences. Former CMO Dr. Robert H. Bartlett, M.D. will retire after nine years with the company, but will remain as a…

ThursdayMay 25, 2017 11:59 am

NetworkNewsBreaks – Shares of Micronet Enertec Technologies, Inc. (NASDAQ: MICT) Surge on Record Backlog of $11.5M

Micronet Enertec Technologies (NASDAQ: MICT) shares are up 14% in morning trade after the developer of customized military computing products said its Micronet Ltd. ("Micronet") subsidiary has received an additional purchase order from a current customer valued at approximately $2.1 million for 8,000 units of its TREQ®-317. This recurring order is expected to be fulfilled during the third and fourth quarters of 2017. A prior purchase order from the same customer, a U.S.-based bulk material supply chain solutions company, was announced in March 2017 and was also valued at $2.1 million. "This order puts our MRM division's backlog at over…

ThursdayMay 25, 2017 11:19 am

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Competes in Key China Market Expected to Reach $48B This Year

As it competes in the huge Chinese sector of online-to-offline marketing, Moxian (NASDAQ: MOXC) has solidified its financial position. Intrigued by the size of China’s O2O market and Moxian’s ambitious strategy for growth, SeeThruEquity has projected that Moxian could achieve revenues of $24.1 million and net income of $4.5 million in FY 2018, providing the company can demonstrate its ability to raise additional capital, as the O2O market is anticipated to reach $48 billion in 1H17. “The high technology Shenzhen, China-based company netted some $8.5 million in an equity offering, at $4 per share, late in 2016 that resulted in…

TuesdayMay 23, 2017 12:09 pm

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Reports 20% Revenue Growth Fueled By North America Transaction Solutions

Net Element (NASDAQ: NETE) recently reported a 20% growth in revenues for the quarter ended March 31, 2017. The company’s North America Transaction Solutions segment was attributed for generating 81% of total sales. “Net revenues for the company were generated principally by payment processing fees in North America, where transactions jumped 40%, exhibiting organic growth, according to Zacks SCR Digest (http://nnw.fm/mTJ49). In 2016, Net Element recorded a 54% jump in North America to $42.1 million. That accounted for about 78% of total company sales for the year.” To view the full article, visit: http://nnw.fm/1vsWa About Net Element Net Element, Inc.…

TuesdayMay 23, 2017 9:15 am

NetworkNewsBreaks – Aegis Capital Issues “Buy” Rating on Fennec Pharmaceuticals, Inc. (FENCF)

Aegis Capital has issued a ‘Buy’ rating and price target of $5 on Fennec Pharmaceuticals (OTCQB: FENCF). The specialty pharmaceuticals company recently reported its corporate update and financial results for the first quarter of 2017, including cash and cash equivalents on hand of $3.3 million, as of March 31, 2017. The analyst expects this should fund operations into 2018. The analyst also noted that the company’s potential new therapy for preventing cisplatin associated ototoxicity, Sodium Thiosulfate (STS), could fill a largely unmet need to avoid negative impact on quality of life. The company is preparing for NDA and MAA submissions,…

ThursdayMay 18, 2017 1:44 pm

NetworkNewsBreaks – Aegis Capital Covers Inovio Pharmaceuticals, Inc. (NASDAQ: INO) with “Buy” Rating, $11 PT

Aegis Capital has issued a ‘Buy’ rating and price target of $11 on shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). The analyst noted that Inovio is awaiting response from the FDA regarding the clinical hold on VGX-3100 phase 3, which is expected to be resolved this month. The company plans to initiate its phase 3 trial with VGX-3100 for HPV-related cervical dysplasia by the second half of 2017. The trial is expected to last approximately two years, with NDA submission in 2020 and product launch in 2021. For more information, visit www.inovio.com About Inovio Pharmaceuticals, Inc. Inovio is taking immunotherapy…

ThursdayMay 18, 2017 1:43 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Aegis Capital has reiterated a ‘Buy’ rating and price target of $25 on shares of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE). The company recently said it has received notice from the FDA that its CTP-543 phase 2a clinical trial for alopecia areata has been placed on clinical hold. The FDA is requesting a review of non-clinical toxicology studies to evaluate the planned one-year dosing. Concert said it intends to submit a response shortly, which the FDA will review within 30 days. The analyst noted the hold and said he believes the issue will be easily resolved without a long delay in…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Breaks Categories: Analyst Alerts